# Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection

> **NCT04818216** · PHASE2 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 28 (actual)

## Conditions studied

- SARS-CoV-2 Infection
- Acute Kidney Injury

## Interventions

- **DRUG:** Placebo
- **DRUG:** Nicotinamide riboside

## Key facts

- **NCT ID:** NCT04818216
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-11
- **Primary completion:** 2021-12-09
- **Final completion:** 2022-01-03
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04818216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04818216, "Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04818216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*